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COMPARISON OF FOUR DIFFERENT EMBOLIC MATERIALS FOR UTERINE 
ARTERY EMBOLIZATION IN POST-PROCEDURE MRI ENHANCEMENT 
Steven D. Abramowitz, Gary M. Israel, Shirley M. McCarthy, Jeffrey S. Pollak, Robert I. White Jr., and 
Michael G. Tal. Department of Radiology, Yale University, School of Medicine, New Haven, CT. 
 
The aim of this study was to assess embolic agent equivalency in uterine artery 
embolization (UAE) using post-procedure MRI enhancement of uterine fibroids in 
patients embolized using Embosphere Microspheres, (EM) Contour SE spheres (CSE), 
Poly-Vinyl Alcohol particles (PVA) and Bead Block spheres (BB). 
A total of 84 women with 6-month MRI follow-up constituted this retrospective 
study. Within this group, 25 women were treated with PVA, 23 were treated with CSE, 
19 were treated with EM and 17 were treated with BB. Pre- and post-procedure MRI 
exams were analyzed for the total number of fibroids present in the uterus of each patient 
and the percentage individual fibroid enhancement of each fibroid was scored in quartile 
intervals. The overall percentage change in enhancement was then calculated for each 
patient. Bivariate analysis using Generalized Linear Modeling and one-way ANOVA was 
used to assess differences in infarction by different embolic materials. 
Of patients treated with PVA and EM, there was a mean reduction in 
enhancement by 76.60% and 83.07%, respectively, compared to a mean reduction of 
52.53% and 49.78% in patients treated with CSE and BB, respectively. There was a 
statistically significant difference between CSE or BB and EM or PVA.  
Patients treated with BB and CSE demonstrate a reduced degree of infarction on 
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 First described in 1793 by Matthew Baillie of St. George’s Hospital, London, 
uterine leiomyomata are the most common benign tumor of the female reproductive 
track. Symptomatic uterine leiomyomata (commonly referred to as “fibroids”) may be 
found in up to 25% of all women and up to 40% of all women over the age of 40. (1, 2) 
Although uterine fibroids are benign, lack premalignant characteristics, and rarely 
damage adjacent anatomic structures, they can cause severe menorrhagia, pain, bulk-
related symptoms and lead to subfertility. 
 Traditionally, women seeking medical assistance for fibroid management are 
treated surgically, as there are no proven effective long-term medical therapies available. 
However, for many women, surgical intervention represents an undesirable solution. 
Surgical therapies such as hysterectomy or myomectomy are invasive and may render 
patients infertile or with questionable fertility. Furthermore, these surgeries both involve 
considerable morbidity. (3) Thus, there an increasing need for a minimally invasive 
treatment alternative emerged from both patients and physicians. 
 Encouraged by the observation that there was an improvement in fibroid-related 
symptoms after patients underwent uterine artery embolization (UAE) for postpartum 
hemorrhage, Rivina et al first described UAE as an acceptable treatment alternative for 
symptomatic uterine fibroids in 1995. (4) The demand for UAE for fibroid management 
was immediately apparent and numerous publications surfaced touting the new minimally 
invasive method of reducing fibroid-related symptom without the need for surgery. (5, 6) 
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It was this subsequent work that has since led to the development of UAE as a tool for 
minimally invasive, uterus-preserving fibroid management.  
Over the past 14 years, multiple embolic agents have become commercially 
available and have been approved by the Food and Drug Administration (FDA) for use in 
the procedure. (7, 8)Numerous technical refinements have also been made to the 
procedure, such as the use of microcatheters, in order to improve post-procedure 
outcomes. While technical improvements to UAE have been carefully researched and 
scrutinized, not as much attention has been focused on comparing and assessing the 
newly emerging embolic agents responsible for the ultimate success of the procedure. (9) 
It is this gap in knowledge that we hope to narrow. 
 




 For decades, physicians have idealized a pill with minimal side effects that would 
lead to fibroid regression and symptom resolution without impacting a woman’s fertility 
status. To date, no effective medical therapy exists that meets these criteria. However, 
there are multiple medical therapies available for the short-term management of fibroid 
symptoms. Most of these therapies are hormonal in nature and rely on manipulating the 
known mechanisms of fibroid development. 
 Since the discovery and initial synthesis of gonadotropin-releasing hormone 
(GnRH), translational research has sought to apply hormone analogues to the treatment of 
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fibroids. Gonadotropin-releasing hormone analogues (GnRHa) are the mostly widely 
used derivatives of this work. GnRHa can cause fibroid regression, limit menorrhagia and 
reduce bulk-related symptoms but only after an initial flare and worsening of symptoms. 
(10)  However, they may only be employed for a short period of time as they cause 
significant osteopenia in pre- and peri-menopasal women. (11, 12) Gonadotropin-
releasing hormone antagonists avoid the symptom flare associated with GnRHa, but carry 
a similar side-effect profile. Cessation of both GnRH-based therapies causes marked 
rebound growth. 
 Selective estrogen receptor modulators have been studied, as well, but they are 
proven efficacious only in post-menopausal women. Thus, they do not benefit the large 
majority of fibroid sufferers. This is also true with aromatase inhibitors. (10) In the pre-
menopausal population, progesterone antagonists, such as mifepristone and asoprisnil, 
cause significant regression in fibroid size, but they, and similar progesterone therapies 
like danazol and gestrinone, are not compatible with reproduction. 
 As a result, most medical therapies are commonly utilized in the pre-operative 
period to reduce leiomyoma size.  
 
  Surgical Intervention   
  
 Traditionally, two surgical procedures are utilized in fibroid management: 
hysterectomy and myomectomy. Although both procedures have considerable morbidity, 
they are performed with relative frequency.(3) Annually, there are almost 600,000 
hysterectomies performed in the United States, of which 30% to 70% are for fibroid 
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management. (13, 14) In comparison, each year there are approximately 35,000 
abdominal, laproscopic and hysteroscopic myomectomies performed for fibroid 
management. (15) 
 
  Hysterectomy 
 
 Hysterectomy is the gold standard treatment of uterine leiomyomata as excision 
of the uterus and accompanying fibroids allow for no chance of recurrence. However, as 
stated before, it can be an undesirable and an extreme treatment in those patients who 
suffer from mild to severe fibroid symptoms as it renders the patients infertile. In many 
women, hysterectomy can also result in issues of sexual dysfunction and psychological 
side effects including depression and a loss of femininity. (16, 17) 
 Despite the frequency with which the surgery is performed, it is not without 
significant risk of complications. Hysterectomy carries a major morbidity rate of 3%, a 
minor morbidity rate of 14% and a mortality rate of 1-2 women per 1000 operations 
performed in major medical centers. (18) The average patient will spend 5.1 days in the 
hospital after the operation. 
For those women who have no complications in the peri-operative period, there 
are still long-term risks.  There is a considerable risk of urinary stress incontinence as 
reported by Altman et al. Altman et al looked at 165260 women who underwent 
hysterectomy and compared their long-term outcomes to a control group of 470506 
women who did not have the operation. They found that rate of urinary stress 
incontinence per 100000 person-years was 179 [95% CI 173-186] in the exposed cohort 
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versus 76 [95% CI 73-76] in the unexposed cohort. (19) There has also been a 
documented increased risk for the need for subsequent pelvic prolapse surgery at a later 
stage. 
 
  Myomectomy 
 
 Myomectomy is a surgical alternative to hysterectomy. During myomectomy, 
fibroids are surgically removed from the myometrium and the uterus is preserved since 
reconstruction is performed. The operation may be performed laproscopically, 
abdominally or hysteroscopically, although hysteroscopic myomectomy is reserved for 
small, submucosal fibroids. (20) 
 Depending upon the method of myomectomy, the surgery carries a major 
morbidity rate of 2% to 5%, a minor morbidity rate of 15% to 29% and a mortality rate of 
2 women per 1000 operations performed in major medical centers. (21) As the uterus is 
highly vascular, all methods of myomectomy carry a risk of hemorrhage with up to 20% 
of cases requiring transfusion. The vascular nature of the uterus also contributes to its 
adhesiogenic properties. Laproscopic or abdominal myomectomy may result in 
significant intra-abdominal adhesions leading to short- and long-term complications such 
as small bowel obstruction. (22)  
 Patients undergoing myomectomy have an average hospital length of stay of 3.8 
days during which there is a high incidence of fever. Patients are also observed for 
infection, continued bleeding, visceral damage from trocar placement, uterine perforation 
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and thromboembolism. These and intra-operative complications lead to an intra-operative 
and short-term hysterectomy conversion rate of 2%. (21)  
 In the long-term, myomectomy patients have a significant rate of fibroid 
recurrence.  A review of 41 studies found the risk for symptomatic fibroid recurrence was 
20% to 50% 5 years from the operation. (23) Women who have had a myomectomy are 
also at risk for rupture during gestation. With respect to fertility, research reports mixed 
results after myomectomy. However, the majority of literature seems to report that 
fertility is improved by myomectomy, as is the risk of miscarriage, when compared to 
those women who did not undergo surgical intervention for fibroid management.  (24) 
  
Uterine Artery Embolization 
 
 Prior to 1995, uterine artery embolization had been successfully used for 
refractory postpartum hemorrhage, for bleeding after gynecologic surgery or pelvic 
trauma and for embolization of pelvic artiovenous malformation. (6, 25) It was in 1995 
that Ravina et al modified the technique for use in fibroid management after noticing 
fibroid symptom improvement in patients that had undergone UAE for one of the above 
stated reasons. (4) The procedure achieves success without uterine compromise because 
blood to leiomyoma comes from end arteries and lack collateral flow supply. Therefore, 
fibroids are preferentially affected by flow reduction as compared normal myometrium 
that quickly acquires new blood flow from collateral vessels.(26) 
 
 Technical Aspects of UAE 
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 The goal of UAE for effective fibroid treatment is the complete devascularization 
of all fibroids via the introduction of particulate embolic agent into both uterine arteries. 
(26) To achieve this goal, the patient is first given analgesia so that they may tolerate the 
procedure. The type of analgesia varies depending upon the interventionalists performing 
the embolization. Local anesthesia, epidural anesthesia, spinal anesthesia, conscious 
sedation, and general anesthesia have all been reported. (27)  
 Once anesthesia is obtained, access is typically achieved via the catheterization of 
a single femoral artery and pelvic arteriography is performed in order to define the 
patient’s vasculature. Bilateral femoral access may be achieved with the benefit of 
reducing radiation exposure and procedure time, however it is generally more 
cumbersome, thus not done. (26) Once femoral access and arteriography is accomplished, 
the contralateral uterine artery is then selectively catheterized. The artery is identified 
using subtraction angiography and arteriography is performed in order to assess uterine 
artery anatomy and the presence of any ovarian collateral vasculature. (25) If the vascular 
anatomy is deemed to be suitable, the embolic agent is then introduced until the agent’s 
angiogenic endpoint is reached. This procedure is then repeated on the ipsilateral uterine 
artery. 
 The procedure usually lasts approximately 1 hour and will expose the patient to 
an average of 20rads of radiation. (5, 28) However, these factors are incredibly operator 
dependant. (29)Patients are usually admitted overnight for observation and pain 
management using non-steroidal anti-inflammatory drugs or narcotics. Extension of 
hospital stay for pain management beyond one night is not uncommon. 
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 The standard of care aims for a technical success rate of 96% in uterine artery 
embolization. (30) The success rate of the procedure may be adversely affected by artery 
tortuosity, small vessel caliber and anatomic variants. However, the introduction of 
microcatheters aids the interventionalist in overcoming these obstacles. (31) Some 
interventionalists choose to microcatheters exclusively to avoid arterial spasm, which, if 
it occurs, may negatively impact technical success rates. If spasm does occur, 




 The ideal treatment for uterine leiomyomata would eliminate symptoms, reduce 
tumor size, limit fibroid recurrence and preserve the patient fertility. Uterine artery 
embolization accomplishes some, if not all, of these objectives. While the data supporting 
uterine artery is overwhelmingly based in case series or prospective oberservational 
studies, the results tend to be consistent.  
 UAE relieves fibroid-related symptoms in the vast majority of patients. (29, 30, 
32) In a study of 5 year long-term results, Kim et al found that 85% to 95% of patients 
reported a reduction in menorrhagia and 40 to 60% of patients reported a reductions in 
bulk-related symptoms. (33) This is consistent with 2 month to 4 month magnetic 
resonance (MR) imaging follow-up that show a decrease of uterine volume from 40% to 
60%. (6) The same study also indicates that when technical success is achieved, the 
reduction of uterine volume continues over time. Further studies have proved that the 
reduction of fibroid symptomatology following UAE is unrelated to the number of 
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fibroids presents, their location or their size and solely related to successful achievement 
of embolic agent angiogenic endpoint. (34) 
 Patients treated with UAE have relatively low rates of short-term recurrence. 
Approximately 10% of patients treated with UAE will have a recurrence of their 
symptoms at 1 year. Of those patients who present with symptom recurrence, 87.5% are 
due to new leiomyoma formation and only 12.5% are due to fibroid regrowth. (35) Long-
term studies assessing fibroid recurrence after UAE indicate that 30% of patients will 
have new leiomyoma formation detected by MR imaging, with only 13% of patients 
reporting symptoms. (33) 
 With respect to a patient’s sexuality and mental health, studies indicate that over 
surgical procedures, those patients who underwent UAE have significantly improved or 
maintained body image. (36) Many women report improved pleasure from and increased 
habit of sexual intercourse after UAE. (37) Moreover, 3 months after UAE women have a 
statistically significant improvement in sexual function and psychological well-being. 
 Currently, there lacks sufficient date to conclude the impact UAE has on fertility. 
(38)Fibroids, especially those that are submucosal, adversely impact fertility via uterine 
distortion. (39) There are no published prospective studies regarding fertility in UAE 
patients that document women who attempt pregnancy after the procedure, therefore 
cycle, conception and fecundity rate are not available. However, the Society of 
Interventional Radiology Foundation is in the process of gathering this data as of 1999 
with the creation of a national fibroid registry. To date, anecdotal evidence is positive 
with many centers reporting normal full-term pregnancy in patients status post UAE.  
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Limited data indicates little to no relation between UAE and impact on gestational term 
or complication rates. 
 Concern does exist that ovarian function may be compromised as a result of 
embolic material in the ovarian blood supply. (6) There is also a question as to whether or 
not decreased vascular supply of the uterine myometrium and endometrium after UAE 
impacts embryo implantation.  However, histological evidence at this point does not 
indicate any significant impact on the surrounding myometrium or ovary despite the 
presence of embolic agent in these tissues. (40) 
 
Comparison to Hysterectomy  
 
Until recently, there was little high quality data comparing UAE to hysterectomy. 
However, in the past 5 years, two randomized controlled trials producing Level 1 data 
have been published comparing these two treatment modalities.  
 The first trial was entitled, “Embolization vs. Hysterectomy for Symptomatic 
Uterine Fibroids (EMMY).” This prospective, randomized multicenter trial had two year 
follow-up for patients in both cohorts. The primary endpoint was the prevention of 
hysterectomy in 75% of those cases receiving UAE. Secondary endpoints regarding 
length of hospital stay, complication and reintervention rates, volume reduction, quality 
of life measures and costs were also assessed.  
Of those patients who underwent UAE for fibroid management, only 23.5% 
underwent hysterectomy at the 2 year endpoint. (41) Thus, the trial established that UAE 
is a non-inferior method of fibroid therapy in comparison to hysterectomy. The 
 15 
reintervention rate for UAE was 28.4% as compared to the reintervention rate of 8% for 
the surgical arm of the study. A large component of the reintervention rate in those 
patients who underwent UAE was due to technical failure. Many critics of the EMMY 
trial argue that this is indicative that the multicenter nature of the trial let to the inclusion 
of inexperienced sites leading to technique error.  
Secondary endpoints in the EMMY trial indicate that there were no statistically 
significant differences in the major and the minor complication rates between UAE and 
hysterectomy. However, those patients who underwent UAE had a statistically significant 
less hospital length of stay at 2.5 days compared to the 5.1 days spent in the hospital 
status post hysterectomy. (41) Patients who underwent UAE also returned to work more 
quickly and with less pain in the first 24 hours in comparison to those patients who 
underwent hysterectomy. 
 The second trial was entitled, “Hysterectomy or Percutaneous Embolization for 
Uterine Leiomyomata (HOPEFUL).” This retrospective cohort study analyzed outcomes 
from patients who underwent either UAE or hysterectomy in the UK. Of those patients 
who underwent UAE, 85% reported a reduction in their symptoms as opposed to 95% of 
those patients who underwent hysterectomy. (42) However, there were fewer major or 
minor complications, 19%, in those patients in the UAE cohort as opposed to 26% in the 
hysterectomy cohort. Additionally, economic data from the study suggest UAE was less 
expensive at £2536 versus £8283 for hysterectomy even with the cost of subsequently 
needed reintervention. (43) Quality of life adjusted years was not statistically significant 
until the value of retaining the uterus was factored into the calculation. 
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 Comparison to Myomectomy  
 
 Currently, there are no large-scale, published randomized controlled trials 
evaluating the outcomes of myomectomy alone versus UAE for the management of 
fibroid tumors. However, there are extensive publications documenting institutional 
results. Broder et al compared long-term outcomes of patients treated with abdominal 
myomectomy versus those treated with UAE. They found that women who were 
embolized were more likely to require further invasive treatment for management of 
leiomyomata, at 29% versus 3%. (13) However, in those patients who underwent UAE 
and did not require subsequent reintervention, 92% of emoblization patients and 90% of 
myomectomy reported symptomatic resolution. Women who underwent embolization 
were more likely to be satisfied with their choice of therapy, though, at 94% versus 79% 
for myomectomy.  
 The best comparisons regarding fibroid recurrence between those patients treated 
with myomectomy and those treated with UAE are not head-to-head studies at this point, 
but rather large single procedure research. Currently, the accepted recurrence rate of 
fibroids in myomectomy patients at 2 years is 15% to 20%. (1) Fedele et al indicated, 
though, that after myomectomy, up to 50% of patients show new leiomyoma 
development at 5 years. (44) This is more, although statistical significance is not know, 
than the accepted recurrence rate of 10% for fibroids after UAE at 1 year and a rate of 
30% regrowth at 5 years. (33, 35) Myomectomy, though, tends to be associated with 
greater morbitidy, even though the coversion rate to hysterectomy in both myomectomy 
and UAE is comparable at about 1% for each. (38) 
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 There are also no randomized controlled trials comparing fertility outcomes after 
UAE versus myomectomy. Currently, there exists a large body of conflicting evidence 
based on institutional experience with both procedures. There, however, limited studies 
indicating that patients may have better rates of conception and lesser rates of miscarriage 
after myomectomy in comparison to UAE. (6) One small retrospective study suggests 
that patients may have higher preterm and malpresentation rates after UAE as opposed to 
myomectomy. (45) Much more research needs to be conducted regarding this issue, 
though, before any definitive comparisons may be made. 
 
 Comparison to all Surgical Interventions 
 
 The “REST” trial (Randomized Controlled Trial of Emblization vs. Surgical 
Treatment for Fibroids) was a multicenter government funded randomized controlled trial 
comparing all surgical interventions to uterine artery embolization. Its endpoint was the 
quality of life at 1 year status post intervention based on the Medical Outcomes Study 36-
Item Short-form General Health Survery (SF-36). Although power calculation dictated an 
enrollment of 200 patients (90% power to detect a 10 point change in SF-36), only 80% 
power was achieved. Nevertheless, there was no statistically significant difference in 
mean SF-36 at 1 year between the UAE and surgical cohorts.  
UAE had a higher minor complication rate of 34% versus 20% for surgical 
outcomes; however, most minor complications for UAE were temporally related and 
relatively near the time of the intervention. There was no statistically significant 
difference in the major complication rate between the two study cohorts. There was a 
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statistically significant difference in the length of hospitalization and 24 hour pain scores 
favoring UAE. Additionally, UAE was cheaper, on average, than surgical intervention at 
£1751 versus £2702. 





 While UAE has proven to be a safe minimally invasive alternative to surgery for 
fibroid management, it is not without its risk. The major complication rate of UAE is 
between 1% and 5%. (46, 47) Serious infection resulting in extended hospitalization and 
major morbidity has been reported in 1% to 2% of patients with increased frequency with 
large fibroid infarction. (48) In 1% of patients, subsequent hysterectomy is needed 
usually to combat degenerating leiomyoma infection or severe postembolization 
syndrome.  
 Postembolization syndrome is most often one of the minor complications in the 
post-procedure period. Nearly one third of patients post-embolization will have low-
grade pyrexia, discomfort and malaise lasting 3 days to 7 days. (27) These symptoms, 
accompanied by leukocytosis secondary to leiomyoma infarction and necrosis as well as 
nausea and vomiting represent postembolization syndrome. This occurs in nearly 15% of 
patients after UAE and may require readmission for monitoring. 
 Many patients also complain of chronic vaginal discharge after UAE. Between 
4% ad 7% of patients have chronic vaginal discharge as a result of fluid accumulation in 
 19 
the infracted leiomyoma that is able to communicate with the endometrial cavity. (46, 49) 
Spontaneous resolution of the discharge occurs in nearly 94% of patients, however in the 
remaining population, hysteroscopic resection of the necrotic fibroid is curative and may 
be required. In fact, post-embolization, nearly 10% of patients require hysteroscopy for 
fibroid extrusion for various reasons. (5, 28, 48) 
 Ovarian failure leading to premature menopause has also been reported in 1% to 
2% of patients. (50) This is most frequently reported in peri-menopausal women. Ovarian 
failure is likely due to embolization of the ovary via undetected collateral utero-ovarian 
arteries. Therefore, although promising for symptom relief, UAE contains unique 
morbidity risks such as postembolization syndrome, infection, primary ovarian failure, 
etc. (51) 
 
 Embolic Agent Options 
 
 Evidence indicates that complete devascularization of all leiomyomata is required 
for effective treatment of and symptomatic resolution of uterine fibroids. (52) However, 
the choice of embolic agent in achieving this goal has remained a divisive topic. Current 
commercially available embolic agents vary widely by size, shape, composition, method 
of delivery and accepted angiographic endpoint. Published research may be found both 
attesting to the efficacy as well as highlighting the failure of each. As more embolic 
agents become available, the quagmire expands. 
 Until 2002, there were only two FDA approved embolic agents for use in UAE. 
The first embolic agent is non-spherical poly-vinyl alcohol (Contour; Target Vascular, 
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Boston Scientific, Marlborough, MA). First used in UAE by Ravina at al, it remains the 
industry gold standard and is the most commonly utilized particulate embolic material 
used in UAE. (4, 8) PVA is considered to be a permanent embolic against since it is not 
biodegradable. (53) Histologic exam after UAE with PVA indicates that the variation in 
particle size tends cause more proximal than distal vessel occlusion.  Occlusion also 
appears to be secondary to platelet aggregation and thrombus formation in the 
intraluminal lattice of polyvinyl alcohol particle as the particles were noted not to occupy 
the entire lumen of the emoblized vessel. (54, 55) This has raised the theoretical concern 
of recanalization of fibroid vasculature via distal non-embolized vessels. (56) However, 
the clinic impact appears to be insignificant with complete infarction of uterine 
leiomyomata being achieved after UAE with PVA so long as the endpoint of complete 
vessel occlusion is achieved. (29) 
The second embolic agent used during this time period was Gelfoam, a water-
insoluble hemostatic embolic prepeared from purified skin gelatin. Gelfoam had been 
frequently used as a biodegradable, intravascular embolic agent prior to its application in 
UAE. Gelfoam promotes hemostasis by providing structural support to thrombus 
formation and by causing an acute foreign body reaction. (53)  Gelfoam resorption 
typically occurs within 7 to 21 days of particulate introduction leading to recanalization 
in 3 weeks to 4 months after UAE. (57) However, despite comparable outcomes to PVA, 
Gelfoam still is not as widely used as PVA or other embolic agents introduced after 2002. 
In November 2002, tris-acryl gelatin microspheres (EM; Embosphere; Biosphere 
Medical, Rockland, MA) received UAE indication from the FDA and rapidly gained 
market share becoming the embolic material of choice for UAE. (8) Tris-acryl gelatin 
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microsphere are thought to offer a theoretical advantage over non-spherical PVA as they 
are more uniform in nature and have been found to have more distal penetration on 
histology than non-spherical PVA. (58) This leads to a theoretically greater uniform and 
targeted embolization of the perifibroid plexus when the embolic endpoint, or “pruned-
tree appearance,” is reached. (9, 56) However, a prospective randomized study 
comparing PVA and EM found no statistically significant difference in the clinical or 
imaging outcomes of the two embolic agents. (59) 
In effort to recapture lost market share, spherical PVA (CSE; Contour SE; Boston 
Scientific, Natick, MA) was developed using the chemical properties of non-spherical 
PVA reengineered into the successful spherical shape of EM. In March 2004, after a 
preliminary animal study suggested embolic equivalence to non-spherical PVA, the FDA 
approved CSE for use in the treatment of uterine fibroids. (60) The same study indicated 
that the inflammatory response to CSE was significantly less than to that of other agents 
tested. This may correlated to recently published data suggesting that there exists a 
statistically significant difference in the clinical outcomes of those patients undergoing 
UAE with CSE as opposed to EM. (9) However, there are not randomized controlled 
trials comparing CSE to other embolic agents. 
The most recent embolic agent approved for use in UAE by the FDA is spherical 
poly-vinyl alcohol hydrogel (BB; Bead Block; Biocompatibles Farnham, UK). Similar in 
composition and chemical structure to spherical PVA (CSE), there are currently no 
clinical studies demonstrating its effectiveness as compared to other materials. There are 
also no histologic studies evaluating the means and method of the agent’s embolic 
effects. Despite this fact, a Terumo survey of Interventional Radiologists at the 2005 
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Society of Interventional Radiology showed that 72% of interventional radiologists 
surveyed believe that BB was a superior embolic agent to PVA and EM. Given concerns 
regarding spherical PVA, careful assessment of the extent of fibroid infarction after 




Given the lack of reliable data regarding newly released embolic agents, the 
purpose of our study was to compare the efficacy of four commonly used embolic agents: 
Embosphere Microspheres, Contour SE spheres, Poly-Vinyl Alcohol particles and Bead 
Block spheres. We tested the hypothesis that not all embolic materials are equivalent, 
using post-procedure MRI fibroid enhancement in patients treated by UAE.  The 
commercially available embolic material evaluated were Embosphere Microspheres 
(EM), Contour SE spheres (CSE), Poly-Vinyl Alcohol particles (PVA) and Bead Block 
spheres (BB). 
 




 Upon receiving approval from our institutional human investigations committee 
for waiver of consent of medical record review, 84 women were enrolled in our Health 
Insurance Portability and Accountability compliant retrospective study. Criteria for study 
inclusion were as follows: pre-menopausal females 25-45 years of age, a clinical 
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diagnosis of symptomatic leiomyomas and pre- and 6 month post-UAE MRI at our 
institution. All patients included in the study underwent UAE at our institution between 
December of 2004 and January of 2006.  
 Each patient underwent UAE with one of the four embolic agents included in our 
study. A total of 84 women had uneventful procedures resulting in bilateral embolization 
per embolic agent endpoint. The mean time to 6 month post-UAE follow-up MRI was 6.6 




 Patients underwent standard bilateral UAE performed by one of three experienced 
interventional radiologists: MT, JP and RW with 8, 15 and 25 years experience 
respectively at the time our study was conducted. Prior to catheterization, patients 
received an intravenous line as well as a local anesthesia. Pelvic aortography was 
acquired using an Omniflush Catheter (Angiodynmaics, Queensbury, NY) from the level 
of the renal arteries in order to evaluate collateral blood supply to the fibroids.(61) 
 Uterine artery access was achieved through a 5-F catheter with the use of a 
coaxial 3-F microcatheter (Renegade Hi-Flow, Target Therapeutics/Boston Scientific, 
Fremont, CA). The microcatheter was advanced over a micro-guide wire using contrast 
as a guide. The microcatheter was maneuvered into the proximal portion of the transverse 
segment of the uterine artery. Embolization was then performed. In the event of spasm, 
embolization was postponed until resolution. 
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 Women received one of four embolic agents: 25 women were treated with Poly-
Vinyl Alcohol particles (Contour; Target Vascular, Boston Scientific, Marlborough, 
MA),19 were treated with trisacryl gelatin microspheres (Embosphere; Biosphere 
Medical, Rockland, MA), 23 were treated with spherical PVA (Contour SE; Boston 
Scientific, Natick, MA) and 19 were treated with compressible microspheres (Bead 
Block; Biocompatibles Farnham, UK). The selection of embolic agent was based upon 
agent availability and the preferences of the interventional radiologist performing the 
procedure. Preparation of the selected embolic agent varied according to the product 
specific specifications. PVA (300-500 µm), CSE particles (500-700 and 700-900 µm) 
and BB (500-700 and 700-900 µm) were suspended in 6-7mL of normal saline and 6-
7mL of nonionic contrast solution. EM (500-700 µm) were mixed with 10mL of contrast 
to obtain a 50% concentration of contrast in the syringe. Embolization endpoint was also 
agent dependent. Sluggish forward flow in the main transverse or ascending uterine 
artery was the angiogenic endpoint for CSE and PVA, whereas sluggish flow with a 
“pruned-tree” appearance was the angiogenic endpoint for BB or EM. 
 Following embolization of both uterine arteries, pelvic aortography was repeated 
in order to evaluate uterine artery perfusion as well as to evaluate for the presence of 
collateral blood supply to the uterus. In some cases where ovarian artery collateral flow 






 Gadolinium-enhanced MR imaging was performed before and approximately 6-
months after UAE for evaluation of fibroids. Imaging was performed using a 1.5 T 
scanner (GE Signa, Milwaukee, WI). Sequences obtained were a localizer, fat-suppressed 
sagittal fast spin-echo scans (TR 6200/TE 104), coronal fast spin-echo scans (TR 
3900/TE 103), axial T1 weighted gradient echo scans (TR 180/TE 2.3, 4.8), and coronal 
3D gradient echo (TR 5.9/1.2/40) pre and post IV gadolinium administration 
(0.1mmol/kg). A timing bolus was used to obtain the arterial phase and three post 
contrast-enhanced scans were obtained during the arterial phase and then at 60, and 120 
seconds after gadolinium administration. Subtraction images of the pre- and post-
gadolinium scans were subsequently performed. The field of view varied from 20 to 28 




Images were evaluated for leiomyoma number and leiomyoma enhancement. 
There was no minimal fibroid size established for inclusion in the study and the number 
of fibroids found in each patient ranged from 1 to 38.The number of fibroids in the uterus 
and their subsequent individual enhancement was determined by a radiologist, GI, with 
eight years experience reading pelvic MRI. The radiologist was blinded to the type of 
embolic agent used and all measurements were taken at the same reading station utilizing 
the same reading methodology to control for multiple measurements. On the pre- and 
post-UAE MRI scans, an enhancement score of 0%, 25%, 50%, 75%, or 100% was 
assigned to each fibroid based on a qualitative estimate of percentage volume showing 
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residual enhancement using the third post-contrast phase 120 seconds after gadolinium 
administration. A score of 0% meant no enhancement of a fibroid, and 100% meant 
complete enhancement of a fibroid. Greater than 25% residual enhancement of a fibroid 
post embolization was considered an incomplete infarction. Baseline MR Imaging was 
evaluated before the post-UAE MRI to determine whether the enhancement pattern was a 
result of the embolization procedure or the result of prior autoinfarction. Both baseline 
and post-UAE MRI were assigned enhancement scores. The studies were read using a 




 Analysis was performed with respect to the number of fibroids present within an 
embolic agent cohort and the change in enhancement from baseline. No power analysis 
was performed, as the cohorts constituted a convenience sample. The overall percentage 
change in enhancement was also calculated for each patient. For each patient, the total 
number of fibroids and their respective enhancement score in pre-UAE and post-UAE 
MR studies was tabulated. The overall percentage change in fibroid enhancement was 
then calculated for each patient as the average change in enhancement of all fibroids 
documented. The mean change in enhancement of leiomyomas caused by each embolic 
agent was then calculated as well as the mean number of leiomyomas present per patient. 
Confidence intervals were calculated with respect to the mean percentage change of 
uterine fibroid enhancement post-embolization for each embolic agent. Bivariate analysis 
was performed using Generalized Linear Modeling and one-way ANOVA were used as 
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statistical tools. Compiled data were analyzed using SAS for Windows 9.1 (version 8.0, 




 Of patients treated with PVA and EM, there was a mean reduction in 
enhancement by 76.60% and 83.07% respectively, compared to a mean reduction of 
52.53% and 49.78% of patients treated with CSE and BB, respectively (Table 1).  
Bivariate analysis showed the following results when comparing embolic agents 
in pairs using 2-tail Fisher’s exact test of least square means: BB to EM resulted in a p = 
0.0153, BB to PVA resulted in a p = 0.0412, CSE to EM resulted in a p = 0.0047 and 
CSE to PVA resulted in a p = 0.0139 (Table 2). One-way ANOVA indicated that there 
was no statistically significant difference in the post-procedural change in enhancement 
between CSE and BB. The change in enhancement between PVA and EM was also non 
significant. However, a statistically significant difference did exist in the post-
embolization change in fibroid enhancement between BB and EM, BeadBlock and PVA, 




Previous studies have sought to compare embolic agents by assessing and 
comparing pre and post-embolization enhancement of the dominant leiomyoma.(52, 63) 
We chose to assess the percentage change in enhancement of individual fibroids in a 
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patient for two reasons. First, research has indicated that there is an association between 
the recurrence of fibroid-related symptoms and the incomplete infarction of fibroids post-
embolization as detected by gadolinium-enhanced MR imaging.(9, 64) Further work has 
also implied that incompletely infarcted fibroids are likely to continue growing after 
embolization increasing a patient’s risk for future symptom recurrence.(52)Therefore, we 
felt that residual enhancement of any fibroid post-embolization would represent a risk for 
symptom return post-UAE since evaluating only the dominant fibroid excludes changes 
in the numerous other fibroids that impact on clinical success. Second, in evaluating the 
total number of fibroids present in each patient, we were also able to determine the mean 
number of fibroids per patient per embolic agent. This allowed us to implement a cross-
cohort control for patient comparison. 
 We found statistically significant differences in the six month post-embolization 
mean percentage enhancement reduction between the tested agents, demonstrating that 
CSE and BB are less effective embolic agents at infarcting fibroids than EM and PVA 
when used according to our protocol. Given previous research, we can infer that those 
patients embolized with BB or CSE are at a higher risk for symptom recurrence than 
those patients embolized with EM or PVA. 
 Previous work in embolic agent comparison corroborates some of our findings. A 
randomized comparative study conducted by Spies et al. also found that trisacryl gelatin 
microspheres were comparable to PVA for post-embolization infarction.(59) Additional 
research also performed by Spies et al. found that spherical PVA had a substantially 
lower likelihood of causing fibroid infarction than trisarcyl gelatin microspheres.(9) 
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 Limitations of our study include possible systemic errors that could have led to 
the differences in residual enhancement. For each embolic agent, we used techniques that 
had differing, albeit thought to be analogous, endpoints. We also strove to ensure that the 
endpoint was stable without collateral flow. The angiogenic endpoint for patients treated 
with CSE and PVA was sluggish-flow or near stasis whereas the angiogenic endpoint for 
patients treated with BB or EM was sluggish flow with a “pruned-tree” appearance. 
Additionally, we used recommended embolic material sizes for each agent. These sizes 
did vary from agent to agent. For the embolic agents SPVA, CSE and BB, we used 500-
700 micron particles with an increase to 700-900 microns in some patients. For PVA, 
300-500 micron particles were used with an increase to 500-700 micron particles in some 
patients. 
 To reduce other technical errors, we followed many previously established 
procedural guidelines as described by Spies et al.(31) Before and after UAE, we 
conducted abdominal aortography to evaluate for enlarged ovarian arteries. Such 
enlargement may contribute collateral flow to the fibroids and impede UAE fibroid 
ablation.(61) We also used micro-catheters during embolization to reduce arterial spasm 
in the uterine arteries, thus preventing a false angiographic endpoint.(31) Taking 
measures to prevent technical failure was especially important given our evaluation of 
efficacy when using various embolic agents. Questions pertaining to the validity of these 
preventative measures, however, fell outside the scope of our study. 
 Another limitation to our study was its size as we described a small, albeit 
statistically significant, group of patients. In large part, this was due to the 
discontinuation of the use of CSE and BB by interventionalists at our institution as 
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retrospective data seemed to show a higher rate of post-procedure enhancement than 
other agents in use. Therefore, there was no opportunity to expand these patient cohorts. 
The resulting small cohort groups may have skewed our results, however there was no 
statistically significant difference between the cohorts with respect to age or the mean 
number of fibroids per patient. Additionally, our assignment of embolic agents to patients 
was neither double-blind nor truly random but based on the preferences of the 
interventional radiologist performing the procedure. 
 Despite these limitations, we feel that the failure of CSE and BB to perform as 
well as EM and PVA raises questions regarding the continued use of both embolic agents 
in UAE. As Spies et al. have stated, it is important to question the quality of evidence 
when accepting new embolic agents into general practice.(9) This statement seemed 
especially apropos given previous work suggesting discrepancies in adequacy between 
CSE and EM and PVA. Our study suggests that BB, an embolic agent recently introduced 
and approved for UAE use, also has a substantially lower likelihood of causing effective 
fibroid tumor infarction than EM or PVA. 
 The reasons for the differences in post-procedural fibroid infarction between CSE, 
PVA, CSE and BB are open to speculation and should be subject to further investigation. 
Evidence has implicated embolic particle migration and particle size and shape in the 
ability of the embolic agent to induce fibroid infarction.(8, 60) Further work should be 
done to evaluate the ability of embolic agents to infarct fibroid tumors in relation to the 
properties of those agents. An understanding of this relationship would further the 
development of new embolic agents to be used in the treatment of leiomyomas. Research 
must also be done to establish appropriate imaging protocols for evaluating the outcomes 
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of new embolic agents prior to their release and to establish acceptable parameters for 
embolic agent infarction efficacy. 
Our data suggests that in the treatment of uterine fibroids by UAE, patients treated 
with Bead Block and Contour SE demonstrate a statistically significant reduced degree of 
infarction on follow-up MRI than those patients treated with classic PVA or Embosphere 
microspheres. Further studies must be done to determine whether or not BB and CSE are 





Table 1 Mean Percentage Change in Post-Uterine Artery Embolization Enhancement 














t Value Pr > | t | Lower 95% 
Upper 
95% 
BB 17 6 1-16 33.7 -52.53 ± 43.96 - 4.93 < 0.0001 -75.13 -29.93 
CSE 23 7 2-20 32.1 -49.78 ± 38.96 -6.13 < 0.0001 -66.63 -32.94 
EM 19 6 2-24 36.4 -83.07 ± 31.54 -11.48 < 0.0001 -98.27 -67.87 





Table 2 ANOVA comparing the mean percentage reduction in post-Uterine Artery Embolization fibroid 
enhancement by embolic agent. 
Agent BB CSE EM PVA 
BB  0.8164 0.0153 0.0412 
CSE 0.8164  0.0047 0.0139 
EM 0.0153 0.0047  0.5662 









Image 1 is a coronal contrast enhanced MR image in a 32 year old woman pre-(A) and 
post-UAE(B). Image 1A is representative of a fibroid that showed 100% enhancement, 
whereas Image 1B is representative of a fibroid that showed 25% enhancement. 
 
Image 2 is a coronal contrast enhanced MR image in a 29 year old woman pre-(A) and 
post-UAE(B). Image 2A is representative of a fibroid that showed 100% enhancement, 
whereas Image 2B is representative of a fibroid that showed 50% enhancement. 
 
Image 3 is a coronal contrast enhanced MR image in a 35 year old woman pre-(A) and 
post-UAE(B). Image 3A is representative of a fibroid that showed 100% enhancement, 
whereas Image 3B is representative of a fibroid that showed 75% enhancement. 
 
Image 4 is a coronal contrast enhanced MR image in a 32 year old woman pre-(A) and 
post-UAE(B). Image 4A is representative of a fibroid that showed 100% enhancement, 



















1. Buttram VC,Jr. Uterine leiomyomata--aetiology, symptomatology and 
management. Prog Clin Biol Res 1986; 225:275-296. 
2. Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of 
uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997; 
90:967-973. 
3. Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: 
abdominal myomectomy and hysterectomy. Clin Obstet Gynecol 2001; 44:385-400. 
4. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. Arterial embolisation to treat 
uterine myomata. Lancet 1995; 346:671-672. 
5. Goodwin SC, McLucas B, Lee M, et al. Uterine artery embolization for the 
treatment of uterine leiomyomata midterm results. J Vasc Interv Radiol 1999; 10:1159-
1165. 
6. Marshburn PB, Matthews ML, Hurst BS. Uterine artery embolization as a 
treatment option for uterine myomas. Obstet Gynecol Clin North Am 2006; 33:125-144. 
7. Katsumori T, Akazawa K, Mihara T. Uterine artery embolization for 
pedunculated subserosal fibroids. AJR Am J Roentgenol 2005; 184:399-402. 
8. Ryu RK. Uterine artery embolization: current implications of embolic agent 
choice. J Vasc Interv Radiol 2005; 16:1419-1422. 
9. Spies JB, Allison S, Flick P, et al. Spherical polyvinyl alcohol versus tris-acryl 
gelatin microspheres for uterine artery embolization for leiomyomas: results of a limited 
randomized comparative study. J Vasc Interv Radiol 2005; 16:1431-1437. 
10. Wu T, Chen X, Xie L. Selective estrogen receptor modulators (SERMs) for 
uterine leiomyomas. Cochrane Database Syst Rev 2007; (4):CD005287. 
11. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of 
leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, 
multicenter study. The Leuprolide Study Group. Obstet Gynecol 1991; 77:720-725. 
12. Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in 
young women treated with GnRH analogues with "add-back" estrogen therapy. Obstet 
Gynecol 1993; 81:104-107. 
13. Broder MS, Goodwin S, Chen G, et al. Comparison of long-term outcomes of 
myomectomy and uterine artery embolization. Obstet Gynecol 2002; 100:864-868. 
14. Lepine LA, Hillis SD, Marchbanks PA, et al. Hysterectomy surveillance--United 
States, 1980-1993. MMWR CDC Surveill Summ 1997; 46:1-15. 
15. Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery embolization versus 
surgery for symptomatic uterine fibroids. N Engl J Med 2007; 356:360-370. 
16. Kjerulff KH, Langenberg PW, Rhodes JC, Harvey LA, Guzinski GM, Stolley PD. 
Effectiveness of hysterectomy. Obstet Gynecol 2000; 95:319-326. 
17. McPherson K, Herbert A, Judge A, et al. Psychosexual health 5 years after 
hysterectomy: population-based comparison with endometrial ablation for dysfunctional 
uterine bleeding. Health Expect 2005; 8:234-243. 
18. McPherson K, Metcalfe MA, Herbert A, et al. Severe complications of 
hysterectomy: the VALUE study. BJOG 2004; 111:688-694. 
19. Altman D, Granath F, Cnattingius S, Falconer C. Hysterectomy and risk of stress-
urinary-incontinence surgery: nationwide cohort study. Lancet 2007; 370:1494-1499. 
 37 
20. Taylor A, Sharma M, Tsirkas P, et al. Surgical and radiological management of 
uterine fibroids--a UK survey of current consultant practice. Acta Obstet Gynecol Scand 
2005; 84:478-482. 
21. Dubuisson JB, Chapron C, Fauconnier A, Kreiker G. Laparoscopic myomectomy 
and myolysis. Curr Opin Obstet Gynecol 1997; 9:233-238. 
22. LaMorte AI, Lalwani S, Diamond MP. Morbidity associated with abdominal 
myomectomy. Obstet Gynecol 1993; 82:897-900. 
23. Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of 
leiomyomata after myomectomy. Hum Reprod Update 2000; 6:595-602. 
24. Palomba S, Zupi E, Falbo A, et al. A multicenter randomized, controlled study 
comparing laparoscopic versus minilaparotomic myomectomy: reproductive outcomes. 
Fertil Steril 2007; 88:933-941. 
25. Goodwin SC, Vedantham S, McLucas B, Forno AE, Perrella R. Preliminary 
experience with uterine artery embolization for uterine fibroids. J Vasc Interv Radiol 
1997; 8:517-526. 
26. Pelage JP, Soyer P, Le Dref O, et al. Uterine arteries: bilateral catheterization with 
a single femoral approach and a single 5-F catheter--technical note. Radiology 1999; 
210:573-575. 
27. Bratby MJ, Belli AM. Radiological treatment of symptomatic uterine fibroids. 
Best Pract Res Clin Obstet Gynaecol 2008; 22:717-734. 
28. Spies JB, Scialli AR, Jha RC, et al. Initial results from uterine fibroid 
embolization for symptomatic leiomyomata. J Vasc Interv Radiol 1999; 10:1149-1157. 
29. Pron G, Bennett J, Common A, et al. Technical results and effects of operator 
experience on uterine artery embolization for fibroids: the Ontario Uterine Fibroid 
Embolization Trial. J Vasc Interv Radiol 2003; 14:545-554. 
30. Bratby MJ, Hussain FF, Walker WJ. Outcomes after unilateral uterine artery 
embolization: a retrospective review. Cardiovasc Intervent Radiol 2008; 31:254-259. 
31. Spies JB. Uterine artery embolization for fibroids: understanding the technical 
causes of failure. J Vasc Interv Radiol 2003; 14:11-14. 
32. Goodwin SC, Spies JB, Worthington-Kirsch R, et al. Uterine artery embolization 
for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet 
Gynecol 2008; 111:22-33. 
33. Kim MD, Lee HS, Lee MH, Kim HJ, Cho JH, Cha SH. Long-term results of 
symptomatic fibroids treated with uterine artery embolization: In conjunction with MR 
evaluation. Eur J Radiol 2008;  
34. Firouznia K, Ghanaati H, Sanaati M, Jalali AH, Shakiba M. Uterine artery 
embolization in 101 cases of uterine fibroids: do size, location, and number of fibroids 
affect therapeutic success and complications? Cardiovasc Intervent Radiol 2008; 31:521-
526. 
35. Marret H, Alonso AM, Cottier JP, Tranquart F, Herbreteau D, Body G. 
Leiomyoma recurrence after uterine artery embolization. J Vasc Interv Radiol 2003; 
14:1395-1399. 
36. Hehenkamp WJ, Volkers NA, Bartholomeus W, et al. Sexuality and body image 
after uterine artery embolization and hysterectomy in the treatment of uterine fibroids: a 
randomized comparison. Cardiovasc Intervent Radiol 2007; 30:866-875. 
 38 
37. Voogt MJ, De Vries J, Fonteijn W, Lohle PN, Boekkooi PF. Sexual functioning 
and psychological well-being after uterine artery embolization in women with 
symptomatic uterine fibroids. Fertil Steril 2008;  
38. Marshburn PB, Matthews ML, Hurst BS. Uterine artery embolization as a 
treatment option for uterine myomas. Obstet Gynecol Clin North Am 2006; 33:125-144. 
39. Eldar-Geva T, Meagher S, Healy DL, MacLachlan V, Breheny S, Wood C. Effect 
of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted 
reproductive technology treatment. Fertil Steril 1998; 70:687-691. 
40. Colgan TJ, Pron G, Mocarski EJ, Bennett JD, Asch MR, Common A. Pathologic 
features of uteri and leiomyomas following uterine artery embolization for leiomyomas. 
Am J Surg Pathol 2003; 27:167-177. 
41. Volkers NA, Hehenkamp WJ, Birnie E, Ankum WM, Reekers JA. Uterine artery 
embolization versus hysterectomy in the treatment of symptomatic uterine fibroids: 2 
years' outcome from the randomized EMMY trial. Am J Obstet Gynecol 2007; 
196:519.e1-519.11. 
42. Dutton S, Hirst A, McPherson K, Nicholson T, Maresh M. A UK multicentre 
retrospective cohort study comparing hysterectomy and uterine artery embolisation for 
the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on 
medium-term safety and efficacy. BJOG 2007; 114:1340-1351. 
43. Wu O, Briggs A, Dutton S, et al. Uterine artery embolisation or hysterectomy for 
the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL 
study. BJOG 2007; 114:1352-1362. 
44. Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L, Villa L. Recurrence of 
fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995; 
10:1795-1796. 
45. Goldberg J, Pereira L, Berghella V, et al. Pregnancy outcomes after treatment for 
fibromyomata: uterine artery embolization versus laparoscopic myomectomy. Am J 
Obstet Gynecol 2004; 191:18-21. 
46. Walker WJ, Carpenter TT, Kent AS. Persistent vaginal discharge after uterine 
artery embolization for fibroid tumors: cause of the condition, magnetic resonance 
imaging appearance, and surgical treatment. Am J Obstet Gynecol 2004; 190:1230-1233. 
47. Spies JB, Spector A, Roth AR, Baker CM, Mauro L, Murphy-Skrynarz K. 
Complications after uterine artery embolization for leiomyomas. Obstet Gynecol 2002; 
100:873-880. 
48. Godfrey CD, Zbella EA. Uterine necrosis after uterine artery embolization for 
leiomyoma. Obstet Gynecol 2001; 98:950-952. 
49. Walker WJ, Pelage JP. Uterine artery embolisation for symptomatic fibroids: 
clinical results in 400 women with imaging follow up. BJOG 2002; 109:1262-1272. 
50. Hurst BS, Stackhouse DJ, Matthews ML, Marshburn PB. Uterine artery 
embolization for symptomatic uterine myomas. Fertil Steril 2000; 74:855-869. 
51. Spies JB, Warren EH, Mathias SD, Walsh SM, Roth AR, Pentecost MJ. Uterine 
fibroid embolization: measurement of health-related quality of life before and after 
therapy. J Vasc Interv Radiol 1999; 10:1293-1303. 
52. Pelage JP, Guaou NG, Jha RC, Ascher SM, Spies JB. Uterine fibroid tumors: 
long-term MR imaging outcome after embolization. Radiology 2004; 230:803-809. 
 39 
53. Siskin GP, Englander M, Stainken BF, Ahn J, Dowling K, Dolen EG. Embolic 
agents used for uterine fibroid embolization. AJR Am J Roentgenol 2000; 175:767-773. 
54. Aziz A, Petrucco OM, Makinoda S, et al. Transarterial embolization of the uterine 
arteries: patient reactions and effects on uterine vasculature. Acta Obstet Gynecol Scand 
1998; 77:334-340. 
55. Siskin GP, Eaton LA,Jr, Stainken BF, Dowling K, Herr A, Schwartz J. Pathologic 
findings in a uterine leiomyoma after bilateral uterine artery embolization. J Vasc Interv 
Radiol 1999; 10:891-894. 
56. Derdeyn CP, Moran CJ, Cross DT, Dietrich HH, Dacey RG,Jr. Polyvinyl alcohol 
particle size and suspension characteristics. AJNR Am J Neuroradiol 1995; 16:1335-
1343. 
57. Barth KH, Strandberg JD, White RI,Jr. Long term follow-up of transcatheter 
embolization with autologous clot, oxycel and gelfoam in domestic swine. Invest Radiol 
1977; 12:273-280. 
58. Chua GC, Wilsher M, Young MP, Manyonda I, Morgan R, Belli AM. 
Comparison of particle penetration with non-spherical polyvinyl alcohol versus trisacryl 
gelatin microspheres in women undergoing premyomectomy uterine artery embolization. 
Clin Radiol 2005; 60:116-122. 
59. Spies JB, Allison S, Flick P, et al. Polyvinyl alcohol particles and tris-acryl 
gelatin microspheres for uterine artery embolization for leiomyomas: results of a 
randomized comparative study. J Vasc Interv Radiol 2004; 15:793-800. 
60. Siskin GP, Dowling K, Virmani R, Jones R, Todd D. Pathologic evaluation of a 
spherical polyvinyl alcohol embolic agent in a porcine renal model. J Vasc Interv Radiol 
2003; 14:89-98. 
61. Binkert CA, Andrews RT, Kaufman JA. Utility of nonselective abdominal 
aortography in demonstrating ovarian artery collaterals in patients undergoing uterine 
artery embolization for fibroids. J Vasc Interv Radiol 2001; 12:841-845. 
62. Barth MM, Spies JB. Ovarian artery embolization supplementing uterine 
embolization for leiomyomata. J Vasc Interv Radiol 2003; 14:1177-1182. 
63. Katsumori T, Nakajima K, Tokuhiro M. Gadolinium-enhanced MR imaging in 
the evaluation of uterine fibroids treated with uterine artery embolization. AJR Am J 
Roentgenol 2001; 177:303-307. 
64. deSouza NM, Williams AD. Uterine arterial embolization for leiomyomas: 
perfusion and volume changes at MR imaging and relation to clinical outcome. 
Radiology 2002; 222:367-374. 
 
